國家衛生研究院 NHRI:Item 3990099045/4632

NHRI > National Institute of Cancer Research > Li-Tzong Chen > Conference Papers/Meeting Abstract > Item 3990099045/4632

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4632

Title:	Cost-minimization analysis of capecitabine for advanced gastric cancer in Taiwan
Authors:	Chang, CS;Chao, Y;Chen, JS;Chen, LT;Chung, CH;Hsieh, RK;Hwang, WS;Yang, L;De Reyder, F
Contributors:	National Institute of Cancer Research
Abstract:	OBJECTIVE: Gastric cancer is the ﬁfth most prevalent cancer and the ﬁfth cause of cancer-related mortality in Taiwan. The objective of this study was to access the cost-effectiveness of capecitabine plus cisplatin (XP) vs. intravenous 5-ﬂuorouracil plus cisplatin (FP) for the treatment of advanced and metastatic gastric cancer (AGC) in Taiwan, from a payer’s (Bureau of National Health Insurance [BNHI]) perspective. METHODS: A cost-minimization analysis (CMA) was conducted by applying clinical outcomes and medical resource utilization (MRU) derived from the phase III ML17032 study. Direct medical costs associated with trial-based MRU were based on Taiwan’s National Health Insurance fee schedule for 2007. Costs associated with intravenous chemotherapy administration and adverse event (AE) management were estimated by an expert panel survey conducted among 12 oncologists. One-way sensitivity analyses were performed on key model parameters by varying the input values by 20%. RESULTS: A trend toward superior progression-free survival was observed in the XP arm (median 5.6 months for XP vs. 5.0 for FP). Patients in the XP arm received 5.2 cycles of therapy vs. 4.6 cycles of FP. Compared to FP, administration of XP required fewer consults per patient (5.2 for XP vs. 22.8 for FP). Chemotherapy drug cost was higher (USD$1712) in the XP arm; however, these cost increments were offset by differences of chemotherapy administration costs (USD$4376) between two arms. AE proﬁles were similar and the cost associated with grade 3/4 AE management were slightly lower (USD $30) in the XP arm. Overall, XP was associated with a cost saving of USD$2691(NTD$87,351). XP remained cost-saving under one-way sensitivity analyses. CONCLUSION: From the Taiwan BNHI perspective, this CMA demonstrates that replacing FP by XP for the treatment of AGC would not only save direct medical costs but also improve health outcomes in Taiwan.
Date:	2008-05
Relation:	Value in Health. 2008 May-Jun;11(3):A64-A65.
Link to:	http://dx.doi.org/10.1111/j.1524-4733.2008.00383_2.x
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1098-3015&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000255945400213
Appears in Collections:	[Li-Tzong Chen] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
ISI000255945400213.pdf		74Kb	Adobe PDF	233	View/Open

Loading...